English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
 
 
DownloadE-Mail
  Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months' anticoagulation since the acute phase

Zabczyk, M., Natorska, J., Bagoly, Z., Sarkady, F., Barath, B., Katona, E., et al. (2020). Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months' anticoagulation since the acute phase. Journal of Physiology and Pharmacology, 71(4), 519-524. doi:10.26402/jpp.2020.4.07.

Item is

Basic

show hide
Genre: Journal Article

Files

show Files
hide Files
:
jpp.2020.4.07.pdf (Publisher version), 172KB
Name:
jpp.2020.4.07.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
Free article
License:
-

Locators

show

Creators

show
hide
 Creators:
Zabczyk, M.1, Author
Natorska, J.1, Author
Bagoly, Z.1, Author
Sarkady, F.1, Author
Barath, B.1, Author
Katona, E.1, Author
Bryk, A.1, Author
Zettl, K.2, Author              
Wisniewski, J. R.2, Author              
Undas, A.1, Author
Affiliations:
1external, ou_persistent22              
2Mann, Matthias / Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Max Planck Society, ou_1565159              

Content

show
hide
Free keywords: COAGULATION FACTOR-XIII; ACTIVATED FACTOR-XIII; D-DIMER; ALPHA-2-ANTIPLASMIN; RESISTANCE; THROMBINPhysiology; factor XIII; alpha 2-antiplasmin; fibrin clot; proteomics; thrombosis; pulmonary embolism; anticoagulant therapy; blood clotting;
 Abstract: Fibrin cross-linking by coagulation factor (F)XIII leads to clot stabilization. Reduced plasma FXIII levels have been reported in acute pulmonary embolism (PE) patients. We investigated the impact of anticoagulant therapy on clot-bound amounts of FXIII and alpha 2-antiplasmin and their associations with fibrin clot properties in patients with PE. Clots generated from plasma of 18 acute symptomatic patients on admission and after a 3-month treatment with rivaroxaban were assessed off anticoagulation using mass spectrometry. Plasma FXIII and alpha 2-antiplasmin activity were determined at the 2 time points along with thrombin generation markers, plasma fibrin clot permeability (K-s), and clot lysis time (CLT). Following anticoagulant therapy, clot-bound FXIII increased from 2.97 (interquartile range, 1.98 - 4.08) to 4.66 (3.5 - 6.9) mg/g protein and alpha 2-antiplasmin from 9.4 (7.2 - 10.6) to 11 (9.5 - 14) mg/g protein (both p < 0.0001). The two parameters showed positive correlation at baseline only (r = 0.63, p = 0.0056). Similarly to clot-bound amounts, plasma FXIII (+25.8%) and alpha 2-antiplasmin activity (+12%) increased at 3 months. Plasma FXIII activity on admission, but not after 3 months since the index PE, was associated with amounts of clot-bound FXIII (r = 0.35, p = 0.043) and alpha 2-antiplasmin (r = 0.47, p = 0.048). At baseline, clot-bound FXIII correlated with plasma F1+2 prothrombin fragments levels (r = 0.51, p = 0.03), while clot-bound alpha 2-antiplasmin correlated with CLT (r = 0.43, p = 0.036). At 3 months associations of clot-bound FXIII and alpha 2-antiplasmin were abolished. This study assessed for the first time changes in the fibrin clot composition following acute PE, suggesting an increase of clot-bound and plasma FXIII and alpha 2-antiplasmin levels after 3 months.

Details

show
hide
Language(s): eng - English
 Dates: 2020
 Publication Status: Published in print
 Pages: 6
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: ISI: 000607230500007
DOI: 10.26402/jpp.2020.4.07
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Journal of Physiology and Pharmacology
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: JAGIELLONIAN UNIV SCHOOL MED, INST PHYSIOLOGY, 31-531 KRAKOW, 16 GRZEGORZECKA, POLAND : POLISH PHYSIOLOGICAL SOC
Pages: - Volume / Issue: 71 (4) Sequence Number: - Start / End Page: 519 - 524 Identifier: ISSN: 0867-5910